U.S. stocks closed narrowly mixed, winding down several turbulent trading days with gains for the week, helped by a rebound in oil and good data.» Read More
Pharma companies are usually considered safety plays. But might they also be growth stocks in disguise?
Jamie Cox of Harris Financial Group is looking past the current "flight to quality" that has dropped Treasury yields so far, and saying where he thinks the money will be heading when it comes flying back.
With the market trading sideways more investors are turning to high yielding dividend stocks. But can you trust these companies to keep pumping out profits?
Fortune Magazine is looking ahead to 2009 with a list of 10 promising stocks. Senior editor Leigh Gallagher says, "When markets return, they return in force. Usually, after a bear market, in the first nine months, the market goes up by an average of 32 percent, so if you wait, you risk missing big momentum."
Five stocks, huge yields, great defense against this volatile market.
As we wait to see what Barack does in the new year, what can you do today to position your investment strategy for an Obama Administration? Here are some ideas.
Health care has been one of the best performing sectors in the S&P 500 this year. Are these stocks good for what ails you?
ExxonMobil is the largest stock in the S&P 500. Wal-Mart, the nearest competitor, is a little more than half that size. ExxonMobil has been notably outperforming the market recently. Since early September, Exxon has been up about 5 percent, while the S&P 500 has been down 30 percent.
General Electric announced that it will maintain its dividend for 2009, giving it an 8.6% yield, based on yesterday's close. See how this compares to the other 29 companies in the Dow.
Does the Food and Drug Administration approve drugs anymore? Or are we seeing the lame-duck leadership at the agency punt any action over to the next administration?
The U.S. government's plan to inject $20 billion into Citigroup failed to fully reassure analysts about financials. So what is safe to invest in now? Tim Harris at JPMorgan Asset Management and Khiem Do at Baring Asset Management offered their sector strategies to CNBC.
As the market remains focused on Citi and the President-elect's midday cabinet announcement there are a few newsworthy things going on in biopharmaland.
Health-care reform is not the only thing big pharmaceuticals have to fear, according to Deutsche Bank's Barbara Ryan. There's also the rapidly-growing dominance of generic prescription drugs. Still, she likes several big-name companies in the field.
This stock's performance is a key barometer for the market, Cramer says.
Even in a down market, there are stocks that buck the trend.
Stocks fell to their lowest levels in two weeks as worries about a global slowdown spooked the market.
The faltering economy makes fixed-income investments look mighty tempting, but Jeff Layman of BKD Wealth Advisors is advising investors not to overlook badly-battered blue-chip stocks.
Investors in alternative energy, technology and infrastructure could be among the biggest beneficiaries.
With the race for the White House over and done, what are the best long-term moves going forward?
John Buckingham of Al Frank Asset Management is ready for a rally — and he names a lot of stocks he expects to ride that rally.